INTRODUCTION

Certolizumab pegol (brand name Cimzia) is a pegylated monoclonal antibody that targets tumor necrosis factor-alpha (TNF-alpha). Certolizumab pegol consists of a Fab fragment of a monoclonal antibody specific to tumor necrosis factor alpha (TNF-α) fused to a polyethylene glycol moiety replacing the Fc antibody region. Certolizumab pegol can be produced in bacterial hosts as it does not require glycosylation for active function. Certolizumab pegol is used in the treatment of a variety of autoimmune and autoinflammatory conditions such as Crohn's disease, rheumatoid arthritis, active psoriatic arthritis, ankylosing spondylitis, axial spondyloarthritis and plaque psoriasis.

This plasmid is designed for expressing Certolizumab pegol in E.coli expression system.

PRODUCT INFORMATION

Item No.: PPBD-44
Shipping: Lyophilized plasmid, or liquid plasmid, or plasmids on filter paper
Storage: -20 °C or 4°C according to instruction
Plasmid Backbone: Expression plasmid, flexible options, custom available
Quality Control: Sequencing validation

DRUG INFORMATION

Generic Name: Certolizumab pegol
Brand Names: Cimzia
Classification: Monoclonal antibody (mAb) / Fusion proteins
Target: Tumor necrosis factor alpha (TNF-α)
Action Type: Inhibitor
Amino Acid Sequence: Identical to DB08904

PROTOCOL FOR PLASMID RECOVERY FROM FILTER PAPER

REFERENCE

Corbett M, Chehadah F, Biswas M, Moe-Byrne T, Palmer S, Soares M, Walton M, Harden M, Ho P, Woolacott N, Bojke L. Certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease-modifying antirheumatic drugs: a systematic review and economic evaluation. Health Technol Assess. 2017 Oct;21(56):1-326.

Contact Us